What is it about?
A subset of EBV-positive Burkitt lymphoma and lymphoblastoid cells are relatively resistant to the action of SAHA. Combining SAHA and bortezomib seems to overcome this resistance.
Featured Image
Why is it important?
This paper describes the mechanism of action of combination of SAHA and bortezomib against a subset of Burkitt lymphoma and EBV-driven lymphoblastoid cells. The drug pair may counteract the function of the latent EBNA3 proteins.
Perspectives
Combination of histone deacetylase and protesome inhibitors may overcome the resistance to apoptosis conferred by the EBNA3 proteins in EBV-transformed B cells.
Dr Alan KS CHIANG
The University of Hong Kong
Read the Original
This page is a summary of: Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines, British Journal of Haematology, August 2014, Wiley,
DOI: 10.1111/bjh.13089.
You can read the full text:
Contributors
The following have contributed to this page
